论文部分内容阅读
目的 :比较头孢哌酮 舒巴坦与头孢他啶对恶性血液病并发严重感染的疗效。方法 :回顾性分析 65例恶性血液病并发严重感染者 (男性 4 4例 ,女性 2 1例 ,年龄 4 0a±s 30a) ,其中 33例用头孢哌酮 舒巴坦 ,32例用头孢他啶 ,均 1.0～ 2 .0g ,加入5%葡萄糖注射液 10 0mL ,iv ,drip ,bid ,均 7～ 10d为一个疗程。结果 :头孢哌酮 舒巴坦组临床有效率61% ( 2 0 / 33) ,痊愈率 4 8% ( 16/ 33) ;头孢他啶组临床有效率 59% ( 19/ 32 ) ,痊愈率 4 1% ( 13/ 32 ) (P >0 .0 5)。 2组药物副作用轻微。结论 :头孢哌酮 舒巴坦与头孢他啶治疗恶性血液病并严重感染者疗效相同。
Objective: To compare the efficacy of cefoperazone and sulbactam versus ceftazidime against severe hematological malignancies. Methods: A retrospective analysis of 65 cases of hematological malignancies complicated by serious infection (44 males and 21 females, age 40a ± s 30a), of which 33 patients were treated with cefoperazone sulbactam and 32 patients with ceftazidime, were 1.0 ~ 2.0 g, add 5% glucose injection 10 0mL, iv, drip, bid, are 7 ~ 10d for a course of treatment. Results: The clinical efficacy rate of cefoperazone sulbactam group was 61% (20/33) and the cure rate was 48% (16/33). The clinical effective rate was 59% (19/32) in ceftazidime group, the recovery rate was 41% (13/32) (P> 0 .0 5). 2 groups of drugs side effects. Conclusion: Cefoperazone sulbactam and ceftazidime have the same curative effect in the treatment of hematological malignancies and severe infections.